Clinical trials: Controlled Hypertension
Pulmonary Arterial Hypertension
Single Ascending Dose Study for Evaluation of Safety, Tolerability and Pharmacokinetics of L606
The primary objective of this study is to evaluate the Pharmacokinetics, Safety and Tolerability of L606 (Liposomal Treprostinil) Inhalation Solution in Single Ascending Dose study design in healthy volunteers.
- Trial name
- NCT04041648
- Testing
- L606 (Liposomal Treprostinil) Inhalation Solution 51ug, L606 Inhalation System
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Pharmosa Biopharm Inc.
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate intraocular pressure (IOP) over a 24-hour period using Simbrinza™ topical ophthalmic suspension.
- Trial name
- NCT01978600
- Testing
- Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension, Timolol Maleate 0.5%
- Volunteers
- 89 people
- Sponsor
- Alcon Research
Pulmonary Arterial Hypertension
A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with…
- Trial name
- NCT03924154
- Testing
- RVT-1201
- Where
- 23 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Altavant Sciences GmbH
Hypertension, Pulmonary, Ventricular Dysfunction, Left
Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics
The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction
- Trial name
- HEARTWORK (NCT01065051)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bayer
Sarcoidosis-associated Pulmonary Hypertension
A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag
Oral selexipag is commercially available in several countries for the treatment of a particular group of pulmonary hypertension (PH) called pulmonary arterial hypertension (PAH).
- Trial name
- SPHINX (NCT03942211)
- Testing
- Selexipag
- Where
- 38 sites in United States, Belgium and 8 more
- Volunteers
- 10 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
- Trial name
- PALM-PAH (NCT07481981)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Hypertension
Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)
The purpose of this study is to evaluate antihypertensive (lowering blood pressure) effectiveness of three combinations of approved study drugs compared to both study drugs being given alone.
- Trial name
- NCT00092209
- Testing
- MK0954A, hydrochlorothiazide (+) losartan potassium
- Volunteers
- 840 people
- Sponsor
- Organon and Co
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
- Trial name
- NCT01615198
- Testing
- Olmesartan, LCZ696
- Where
- 79 sites in China, Hong Kong and 5 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with chlorthalidone in treating individuals with essential hypertension, compared to treatment with…
- Trial name
- NCT00591773
- Testing
- Azilsartan medoxomil and chlorthalidone, Chlorthalidone
- Where
- 46 sites in United States
- Volunteers
- 551 people
- Sponsor
- Takeda
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
This study will evaluate the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension
- Trial name
- NCT00413049
- Testing
- Valsartan/amlodipine 80/5 mg, Amlodipine 5 mg
- Where
- 12 sites in China
- Volunteers
- 698 people
- Sponsor
- Novartis
High Risk Cardiovascular Disease, Hypertension
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events.
- Conditions
- High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
- Trial name
- ZENITH (NCT07181109)
- Testing
- Zilebesiran
- Where
- 1,190 sites in United States, Argentina and 33 more
- Volunteers
- 11,000 people
- Sponsor
- Alnylam Pharmaceuticals
Resistant Hypertension
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
The purpose of this 20-week randomized double-blind study in patients with resistant hypertension (rHTN) is to evaluate the efficacy, safety, and tolerability, of different doses of XXB750 administered as subcutaneous (SC)…
- Trial name
- NCT05562934
- Testing
- XXB750 drug
- Where
- 78 sites in United States, Australia and 14 more
- Volunteers
- 189 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Valsartan Alone
This study will test the effectiveness and safety of a combination treatment in patients whose blood pressure is not controlled with a single medication
- Trial name
- NCT00170963
- Testing
- valsartan/amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 1,018 people
- Sponsor
- Novartis
Primary Arterial Hypertension
Effects of Nebivolol on Subclinical Left Ventricular dySfunction: A Comparative Study Against Metoprolol
Summary: Study title: Effects of Nebivolol on subclinical left ventricular dysfunction. A comparative study against Metoprolol. (ENESYS study) Study phase: 3 Study design (parallel, cross-over, etc.), randomisation and blinding…
- Trial name
- ENESYS (NCT00942487)
- Testing
- Nebilet, Corvitol
- Where
- Romania
- Volunteers
- 60 people
- Sponsor
- Berlin-Chemie Menarini
Hypertension
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension
To identify dose combinations of telmisartan and ramipril that are more effective in reducing diastolic blood pressure than each of the respective monotherapies in patients with Stage I or II hypertension.
- Trial name
- NCT00281593
- Testing
- Telmisartan, Ramipril
- Where
- 119 sites in United States, Argentina and 4 more
- Volunteers
- 1,354 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients
This trial will compare valsartan and amlodipine combination therapies to valsartan and amlodipine monotherapy,and placebo for treating patients with hypertension
- Trial name
- NCT00409643
- Testing
- valsartan+amlodipine combination, valsartan, amlodipine
- Where
- 2 sites in United States, Germany
- Volunteers
- 1,259 people
- Sponsor
- Novartis
Hypertension
A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension
To compare the safety and efficacy of an aliskiren-based regimen to a lisinopril-based regimen in the treatment of severe hypertension
- Trial name
- NCT00219050
- Testing
- aliskiren
- Where
- 4 sites in Germany, Hungary and 2 more
- Volunteers
- 180 people
- Sponsor
- Novartis
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
Compare the safety and efficacy of amlodipine besylate and candesartan cilexetil combination therapy on patients of essential hypertension who are not properly controlled by candesartan cilexetil monotherapy.
- Trial name
- NCT02368652
- Testing
- Candesartan cilexetil 16mg, Amlodipine 10mg, Candesartan cilexetil 16mg
- Where
- 19 sites in South Korea
- Volunteers
- 181 people
- Sponsor
- HK inno.N Corporation